Finance

Lists
AMRN:NASDAQ
Amarin Corporation PLC
$14.41
+0.07%
(+0.010) 1D
Aug 5, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AMRN...
Open
$14.35
High
$14.58
Low
$14.10
Mkt. cap
304.38M
Avg. vol.
74.14K
Volume
29.94K
52-wk high
$20.90
52-wk low
$13.12
EPS
-$1.30
Beta
0.81
Shares outstanding
21.12M
No. of employees
80
Open
$14.35
High
$14.58
Low
$14.10
Mkt. cap
304.38M
Avg. vol.
74.14K
Volume
29.94K
52-wk high
$20.90
52-wk low
$13.12
EPS
-$1.30
Beta
0.81
Shares outstanding
21.12M
No. of employees
80
News stories
From sources across the web
Profile
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid. In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza. Wikipedia
About Amarin Corporation PLC
CEO-
Employees80
FoundedMar 1, 1989
HeadquartersDublin, Leinster, Ireland
SectorBiotechnology
Websiteamarincorp.com
Analyst
Recommendation
Action
Price target
Projected
Date
Paul Choi
Goldman Sachs
Sell
Maintained
$12.00
-16.7%
02/25/2026
Jessica Fye
J.P. Morgan
Sell
Maintained
$10.00
-30.6%
10/17/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
49.67M
49.22M
45.13M
42.21M
Cost of goods sold
27.46M
26.05M
27.36M
27.22M
Cost of revenue
27.46M
26.05M
27.36M
27.22M
Research and development expenses
4.21M
5.37M
4.66M
4.77M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19.70M
20.06M
21.12M
22.19M
Operating expense
23.90M
25.43M
25.78M
26.96M
Total operating expenses
51.37M
51.48M
53.14M
54.18M
Operating income
-1.70M
-2.26M
-8.01M
-11.97M
Other non operating income
205.00K
3.60M
188.00K
1.09M
EBT including unusual items
-8.12M
-852.00K
-8.72M
-7.87M
EBT excluding unusual items
1.29M
3.21M
-5.40M
-7.83M
Income tax expense
-377.00K
372.00K
1.79M
-219.00K
Effective tax rate
4.65%
-43.66%
-20.51%
2.78%
Other operating expenses
-
-
-
-
Net income
-7.74M
-1.22M
-10.51M
-7.65M
Net profit margin
-15.58%
-2.49%
-23.29%
-18.12%
Earnings per share
0.19
0.01
-
-
Interest and investment income
2.78M
2.58M
2.42M
3.05M
Interest expense
-
-7.00K
-
-
Net interest expenses
2.78M
2.57M
2.42M
3.05M
Depreciation and amortization charges
-
-
-
-
EBITDA
-830.00K
-1.56M
-7.37M
-11.33M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps